Low preoperative skeletal muscle index increases the risk of mortality among resectable pancreatic cancer patients: A retrospective study

doi:10.4240/wjgs.v14.i12.1350

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2563)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

128

WORD

HTML

1165

Figures (1-3)

143

Tables (1-3)

113

Sum=1586

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

178

Download

799

Sum=977

Dec 27, 2022 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Dec 27, 2022; 14(12): 1350-1362
Published online Dec 27, 2022. doi: 10.4240/wjgs.v14.i12.1350

Table 1 Patient and tumor characteristics comparing low and high skeletal muscle index or radiodensity

Characteristics	Total (n = 115)	Low SMI (n = 38)	High SMI (n = 77)	P value	Low SMD (n = 26)	High SMD (n = 89)	P value
Age	65.1 (9.0)	68.8 (9.3)	63.3 (8.4)	0.002^b	70.8 (7.0)	63.5 (8.9)	< 0.001^c
Male sex	71 (61.7)	29 (76.3)	42 (54.5)	0.024^a	13 (50.0)	58 (65.2)	0.162
BMI in kg/m²	22.7 (3.3)	20.9 (3.1)	23.6 (3.0)	< 0.001^c	24.0 (4.0)	22.3 (2.9)	0.016^a
< 20.0	21(18.3)	14 (36.8)	7 (9.1)		5 (19.2)	16 (18.0)
20.0-24.9	69 (60.0)	20 (52.6)	49 (63.6)		10 (38.5)	59 (66.3)
≥ 25.0	25 (21.7)	4 (10.5)	21 (27.3)	0.001^b	11 (42.3)	14 (15.7)	0.01^a
Albumin in g/dL	42.5 (5.6)	40.6 (4.1)	43.5 (6.1)	0.01^a	41.7 (7.7)	42.8 (4.9)	0.393
Tumor location
Head	67 (58.3)	29 (76.3)	38 (49.4)		18 (69.2)	49 (55.1)
Body + tail	48 (41.7)	9 (23.7)	39 (50.6)	0.006^b	8 (30.8)	40 (44.9)	0.197
Tumor size in cm	3.6 (1.4)	3.7 (1.7)	3.3 (1.2)	0.942	3.3 (1.3)	3.6 (1.4)	0.602
Differentiation
Well	5 (4.3)	1 (2.7)	4 (5.3)		3 (12.0)	4 (4.6)
Moderate	100 (87.0)	31 (83.8)	69 (92.0)		19 (76.0)	81 (93.1)
Poor	7 (6.1)	5 (13.5)	2 (2.7)	0.04^a	3 (12.0)	2 (2.3)	0.774
Nodal metastases	64 (55.7)	20 (52.6)	44 (57.1)	0.647	12 (46.2)	52 (58.4)	0.268
Perineural invasion¹	81 (86.2)	27 (87.1)	54 (85.7)	0.855	25 (100)	56 (81.2)	0.046^a
R1 resection	13 (11.3)	3 (7.9)	10 (13.2)	0.602	3 (11.5)	10 (11.4)	1.000
Adjuvant therapy	84 (73.0)	24 (63.2)	60 (77.9)	0.093	18 (69.2)	66 (74.2)	0.618
TNM stage
I	43 (37.4)	14 (36.8)	29 (37.7)		14 (53.8)	29 (32.6)
II	57 (49.6)	19 (50.0)	38 (49.4)		10 (38.5)	47 (52.8)
III	15 (13.0)	5 (13.1)	10 (13.0)	0.996	2 (7.6)	13 (14.6)	0.135
CA19-9 > 200 KU/L	71 (61.7)	24 (66.7)	47 (63.5)	0.746	21 (84.0)	50 (58.8)	0.021^a
SMA in cm²	123.0 (30.6)	108.4 (19.9)	130.2 (32.4)	< 0.001^c	113.2 (28.4)	125.9 (30.7)	0.056
SMD in HU	39.4 (8.6)	38.5 (10.0)	39.8 (7.8)	0.462	28.5 (5.1)	42.6 (6.5)	< 0.001^c
SMI in cm²/m²	44.6 (9.8)	38.1 (5.3)	47.7 (10.0)	< 0.001^c	41.1 (9.0)	45.6 (9.9)	0.033^a
VAT in cm²	113.4 (66.5)	89 (50.2)	125.4 (70.5)	< 0.001^c	151.0 (60.2)	102.4 (64.5)	0.001^b
SAT in cm²	121.4 (64.6)	100.5 (45.4)	131.7 (70.2)	0.014^a	160.0 (89.3)	110.1 (50.7)	< 0.001^c
NLR > 2.6	44 (38.3)	16 (42.1)	28 (36.4)	0.551	13 (50.0)	31 (34.8)	0.162
PLR > 108	77 (67.0)	27 (71.1)	50 (64.9)	0.512	21 (80.8)	56 (62.9)	0.089
SIII > 400	68 (59.1)	24 (63.2)	44 (57.1)	0.537	17 (65.4)	51 (57.3)	0.461

¹Data were available for 94 patients. Statistics are presented as the means (standard deviations) for age, body mass index, albumin, tumor size, and body composition parameters and n (%) for the other parameters.

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

SMA: Skeletal muscle area; SMD: Skeletal muscle radiodensity; HU: Hounsfield units; SMI: Skeletal muscle index; VAT: Visceral adipose tissue; SAT: Subcutaneous adipose tissue; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SIII: Systemic immune-inflammation index; BMI: Body mass index; CA19-9: Carbohydrate antigen 19-9.

Table 2 Univariate and multivariate analyses of risk factors for overall survival following pancreatic cancer resection

Factor	Univariate analysis	P value	Multivariate analysis	P value
Factor	HR (95%CI)	P value	HR (95%CI)	P value
Age ≥ 65 yr	1.661 (0.905-3.051)	0.102
Male sex	0.686 (0.371-1.267)	0.228
BMI < 20.0 underweight	0.534 (0.262-1.085)	0.083
BMI ≥ 25.0 obesity	0.631 (0.322-1.233)	0.178
Albumin < 3.8 g/dL	1.146 (0.550-2.388)	0.716
Low SMI	2.805 (1.559-5.045)	0.001^b	2.307 (1.210-4.402)	0.011^a
Low SMD	2.395 (1.261-4.550)	0.008^b	2.093 (1.000-4.379)	0.05
Tumor location, head	1.620 (0.870-3.019)	0.128
Tumor size > 2 cm	1.107 (0.494-2.480)	0.805
Differentiation poor	3.102 (0.947-10.158)	0.061
Nodal metastases	1.853 (1.022-3.358)	0.042^a	2.308 (1.200-4.442)	0.012^a
Perineural invasion	2.303 (0.701-7.564)	0.169
R1 Resection	1.165 (0.415-3.267)	0.772
TNM stage III	1.515 (0.673-3.414)	0.316
Adjuvant therapy	0.528 (0.284-0.980)	0.043^a	0.480 (0.242-0.952)	0.036^a
CA19-9 > 200 KU/L	1.891 (1.021-3.504)	0.043^a	0.851 (0.428-1.689)	0.644
NLR > 2.6	1.630 (0.911-2.916)	0.099
PLR > 108	2.208 (1.150-4.238)	0.017^a	1.296 (0.517-3.250)	0.58
SIII > 400	1.911 (1.044-3.500)	0.036^a	1.338 (0.586-3.057)	0.489

^aP < 0.05.

^bP < 0.01.

HR: Hazard ratio; BMI: Body mass index; CA19-9: Carbohydrate antigen 19-9; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SIII: Systemic immune-inflammation index; SMI: Skeletal muscle index; SMD: Skeletal muscle radiodensity; CI: Confidence interval.

Table 3 Univariate and multivariate analysis of risk factors for recurrence-free survival following pancreatic cancer resection

Factor	Univariate analysis	P value	Multivariate analysis	P value
Factor	HR (95%CI)	P value	HR (95%CI)	P value
Age > 65 yr	1.661 (0.905-3.051)	0.102
Male sex	0.631 (0.382-1.041)	0.071
BMI < 20.0 underweight	1.216 (0.660-2.240)	0.530
BMI ≥ 25.0 obesity	1.823 (0.969-3.430)	0.062
Albumin < 3.8 g/dL	0.871 (0455-1.668)	0.677
Low SMI	1.784 (1.083-2.939)	0.023^a	1.907 (1.147-3.171)	0.013^a
Low SMD	1.567 (0.885-2.773)	0.123
Tumor location, head	1.327 (0.795-2.215)	0.278
Tumor size > 2 cm	1.611 (0.767-3.382)	0.208
Differentiation poor	0.978 (0.238-4.022)	0.976
Nodal metastases	1.897 (1.134-3.174)	0.015^a	1.922 (1.129-3.272)	0.016^a
Perineural invasion	1.886 (0.841-4.231)	0.124
R1 Resection	1.593 (0.754-3.365)	0.222
TNM stage III	1.703 (0.833-3.483)	0.144
Adjuvant therapy	0.866 (0.479-1.567)	0.635
CA19-9 in Ku/L > 200	1.439 (0.855-2.421)	0.170
NLR > 2.6	1.071 (0.648-1.769)	0.789
PLR > 108	1.612 (0.955-2.722)	0.074
SIII > 400	1.827 (1.097-3.043)	0.021^a	1.655 (0.984-2.785)	0.058
Platelets > 310 × 10⁹	1.245 (0.533-2.910)	0.613

^aP < 0.05.

Citation: Cai ZW, Li JL, Liu M, Wang HW, Jiang CY. Low preoperative skeletal muscle index increases the risk of mortality among resectable pancreatic cancer patients: A retrospective study. World J Gastrointest Surg 2022; 14(12): 1350-1362
URL: https://www.wjgnet.com/1948-9366/full/v14/i12/1350.htm
DOI: https://dx.doi.org/10.4240/wjgs.v14.i12.1350